Jane E. Ambler
About
Jane E. Ambler is a scholar working on Pharmacology, Molecular Medicine and Infectious Diseases.
According to data from OpenAlex, Jane E. Ambler has authored 24 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pharmacology, 13 papers in Molecular Medicine and 12 papers in Infectious Diseases. Recurrent topics in Jane E. Ambler's work include Antibiotics Pharmacokinetics and Efficacy (14 papers), Antibiotic Resistance in Bacteria (13 papers) and Antimicrobial Resistance in Staphylococcus (12 papers). Jane E. Ambler is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (14 papers), Antibiotic Resistance in Bacteria (13 papers) and Antimicrobial Resistance in Staphylococcus (12 papers). Jane E. Ambler collaborates with scholars based in United States, United Kingdom and Germany. Jane E. Ambler's co-authors include L. Mark Fisher, Shaheen Mehtar, Xiao-Su Pan, Laura Koeth, Tanis C. Dingle, Dwight J. Hardy, Barbara Zimmer, Susan M. Butler‐Wu, Janet A. Hindler and Stephanie L. Mitchell and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Clinical Microbiology and Antimicrobial Agents and Chemotherapy.
In The Last Decade
Jane E. Ambler
24 papers receiving 1.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jane E. Ambler United States | 12 | 533 | 495 | 440 | 308 | 283 | 24 | 1.2k | ||
| Elisabeth Löwdin Sweden | 18 | 737 1.4× | 687 1.4× | 432 1.0× | 159 0.5× | 334 1.2× | 34 | 1.3k | ||
| Chris M. Pillar United States | 23 | 573 1.1× | 484 1.0× | 287 0.7× | 341 1.1× | 623 2.2× | 45 | 1.4k | ||
| Alisa W. Serio United States | 17 | 582 1.1× | 369 0.7× | 235 0.5× | 472 1.5× | 175 0.6× | 38 | 1.4k | ||
| M Visalli United States | 20 | 946 1.8× | 613 1.2× | 538 1.2× | 370 1.2× | 292 1.0× | 32 | 1.6k | ||
| Laura Koeth United States | 12 | 336 0.6× | 237 0.5× | 254 0.6× | 250 0.8× | 380 1.3× | 35 | 1.1k | ||
| N. Brenwald United Kingdom | 18 | 709 1.3× | 704 1.4× | 786 1.8× | 238 0.8× | 411 1.5× | 27 | 1.5k | ||
| Sandrine Lemaire Belgium | 23 | 464 0.9× | 406 0.8× | 263 0.6× | 509 1.7× | 766 2.7× | 43 | 1.5k | ||
| Wenchi Shang United States | 18 | 876 1.6× | 462 0.9× | 462 1.1× | 266 0.9× | 344 1.2× | 22 | 1.3k | ||
| C J Soussy France | 8 | 591 1.1× | 360 0.7× | 326 0.7× | 189 0.6× | 213 0.8× | 14 | 1.2k | ||
| Cristina Seral Spain | 21 | 524 1.0× | 356 0.7× | 291 0.7× | 509 1.7× | 820 2.9× | 57 | 1.8k |
Countries citing papers authored by Jane E. Ambler
Since
Specialization
Citations
This map shows the geographic impact of Jane E. Ambler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane E. Ambler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane E. Ambler more than expected).
Fields of papers citing papers by Jane E. Ambler
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jane E. Ambler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane E. Ambler. The network helps show where Jane E. Ambler may publish in the future.
Co-authorship network of co-authors of Jane E. Ambler
This figure shows the co-authorship network connecting the top 25 collaborators of Jane E. Ambler. A scholar is included among the top collaborators of Jane E. Ambler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane E. Ambler. Jane E. Ambler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fowler, Vance G., Anita Das, Jane E. Ambler, et al.. (2024). Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT). Clinical Infectious Diseases. 78(6). 1473–1481.
2.
Vila‐Farrés, Xavier, Jun Kyun Oh, Steven M. Swift, et al.. (2023). Rapid bacteriolysis of Staphylococcus aureus by lysin exebacase. Microbiology Spectrum. 11(5). e0190623–e0190623.
3.
Oh, Jun Kyun, Matthew A. Warner, Jane E. Ambler, & Raymond Schuch. (2023). The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics. Microbiology Spectrum. 11(2). e0526122–e0526122.
4.
Ambler, Jane E., et al.. (2021). Development of a Broth Microdilution Method for Exebacase Susceptibility Testing. Antimicrobial Agents and Chemotherapy. 65(7). e0258720–e0258720.
5.
Traczewski, Maria M., Jane E. Ambler, & Raymond Schuch. (2021). Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity. Journal of Clinical Microbiology. 59(7). e0311720–e0311720.
6.
Mendes, Rodrigo E., et al.. (2021). 1059. In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-resistant Subsets. Open Forum Infectious Diseases. 8(Supplement_1). S621–S622.
7.
Humphries, Romney M., Jane E. Ambler, Stephanie L. Mitchell, et al.. (2018). CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests. Journal of Clinical Microbiology. 56(4).
8.
Singh, Renu, Mashal M. Almutairi, Richard A. Alm, et al.. (2017). Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model. Journal of Antimicrobial Chemotherapy. 72(10). 2796–2803.
9.
Koeth, Laura, Petra Apfalter, Karsten Becker, et al.. (2016). Multi-center and multi-method evaluation of in vitro activities of ceftaroline against S. aureus. Diagnostic Microbiology and Infectious Disease. 85(4). 452–458.
10.
Lahiri, Sushmita D., Robert E. McLaughlin, James Whiteaker, Jane E. Ambler, & Richard A. Alm. (2015). Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint forStaphylococcus aureus: the role of PBP2a in the activity of ceftaroline. Journal of Antimicrobial Chemotherapy. 70(9). 2488–2498.
11.
Biedenbach, Douglas J., Daryl J. Hoban, E Reiszner, et al.. (2015). In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program. Antimicrobial Agents and Chemotherapy. 59(12). 7873–7877.
12.
Koeth, Laura, Erika Matuschek, Gunnar Kahlmeter, Richard A. Alm, & Jane E. Ambler. (2014). Development of EUCAST zone diameter breakpoints and quality control range for Staphylococcus aureus with ceftaroline 5-μg disk. European Journal of Clinical Microbiology & Infectious Diseases. 33(9). 1511–1517.
13.
Ambler, Jane E., Robert Rennie, James A. Poupard, et al.. (2008). Determination of moxifloxacin anaerobic susceptibility breakpoints according to the Clinical and Laboratory Standards Institute guidelines. Diagnostic Microbiology and Infectious Disease. 61(1). 49–57.
14.
Fogarty, Charles, et al.. (2005). Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia. International Journal of Clinical Practice. 59(11). 1253–1259.
15.
Gillespie, Stephen H., et al.. (2003). Fluoroquinolone Resistance in Streptococcus pneumoniae : Evidence That gyrA Mutations Arise at a Lower Rate and That Mutation in gyrA or parC Predisposes to Further Mutation. Microbial Drug Resistance. 9(1). 17–24.
16.
Scarano, Simona, et al.. (2001). Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens. International Journal of Antimicrobial Agents. 18(4). 379–382.
17.
Ambler, Jane E., et al.. (2001). In Vitro Activity of Gemifloxacin (SB-265805) Compared to Eleven Other Antimicrobial Agents Against Streptococcal Isolates, Excluding Streptococcus pneumoniae. European Journal of Clinical Microbiology & Infectious Diseases. 20(4). 271–275.
18.
Ambler, Jane E. & R. J. Pinney. (1996). Post-UV survival of Escherichia coli strains carrying more than one UV-sensitising plasmid. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 351(2). 181–186.
19.
Ambler, Jane E. & R. J. Pinney. (1995). Positive R plasmid mutator effect on chromosomal mutation to nalidixic acid resistance in nalidixic acid-exposed cultures of Escherichia coli. Journal of Antimicrobial Chemotherapy. 35(5). 603–609.
20.
Ambler, Jane E., et al.. (1993). Mutator plasmid in a nalidixic acid-resistant strain of Shigella dysenteriae type 1. Journal of Antimicrobial Chemotherapy. 31(6). 831–839.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Elisabeth Löwdin Breakdown of academic impact, for papers by Chris M. Pillar Breakdown of academic impact, for papers by Alisa W. Serio Breakdown of academic impact, for papers by M Visalli Breakdown of academic impact, for papers by Laura Koeth Breakdown of academic impact, for papers by N. Brenwald Breakdown of academic impact, for papers by Sandrine Lemaire Breakdown of academic impact, for papers by Wenchi Shang Breakdown of academic impact, for papers by C J Soussy Breakdown of academic impact, for papers by Cristina Seral